Source comparison
Research Timeline Phases: Acute vs Chronic Response Windows
Tesamorelin studies operate across two distinct response windows, and conflating them is the single most common design error we've observed. The acute phase (days 1–14) captures hormonal changes. GH secretion, IGF-1 elevation, insulin sensitivity shifts. The c
This comparison does not assign a generated winner or score.
- Tesamorelin studies operate across two distinct response windows, and conflating them is the single most common design error we've observed. The acute phase (days 1–14) captures hormonal changes. GH secretion, IGF-1 elevation, insulin sensitivity shifts. The chronic phase (weeks 12–26) captures metabolic outcomes. VAT reduction, lean mass changes, lipid profile correction. Both are valid research endpoints, but they're measuring fundamentally different things.
- In the acute phase, tesamorelin's effect on GH secretion is dose-dependent and reproducible. A 2018 Phase 2 trial tested doses ranging from 1mg to 3mg daily and found peak GH levels occurred uniformly at the 2–4 hour mark regardless of dose, but total GH AUC (area under the curve) scaled linearly with dose. This phase is useful for pharmacokinetic studies, receptor occupancy modeling, and dose-response characterisation. But it tells you nothing about whether the peptide will actually reduce fat or improve metabolic markers.
- The chronic phase is where clinical relevance emerges. The pivotal trials that led to tesamorelin's FDA approval for HIV-associated lipodystrophy (under the brand name Egrifta) measured VAT reduction at 26 weeks using CT imaging. Mean VAT reduction was 15.2% in the tesamorelin group vs 4.1% in placebo, with the effect size becoming detectable around week 12 and plateauing by week 20–24. Lipid markers (triglycerides, LDL-C) followed a similar trajectory. Modest improvement at week 8, statistically significant at week 16–20.
- Researchers designing tesamorelin protocols need to declare upfront which phase they're studying. If the endpoint is hormonal (GH, IGF-1), an 8-week trial is sufficient. If the endpoint is metabolic (VAT, lean mass, glucose tolerance), anything shorter than 16 weeks risks Type II error. Concluding the peptide doesn't work when in reality the observation window was too narrow.